Gilead Sciences | GILD - Trade Debtors

Stock Price
152.50
Daily Change
3.13 2.10%
Monthly
22.64%
Yearly
58.79%
Q1 Forecast
137.58

Gilead Sciences reported $5.1B in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Agios Pharmaceuticals USD 5.03M 43K Sep/2025
ALKERMES USD 355.11M 1.22M Sep/2025
Alnylam Pharmaceuticals USD 964.77M 397.66M Sep/2025
Amgen USD 8.49B 211M Sep/2025
Biogen USD 1.85B 234M Sep/2025
BioMarin Pharmaceutical USD 790.27M 65.59M Sep/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Gilead Sciences USD 5.1B 314M Sep/2025
GlaxoSmithKline GBP 7.76B 545M Dec/2025
Glaxosmithkline GBP 11.16B 3.46B Sep/2025
Incyte USD 895.89M 53M Sep/2025
J&J USD 17.61B 235M Sep/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 1.05B 589M Sep/2025
Neurocrine Biosciences USD 728M 132.3M Sep/2025
Novartis USD 8.98B 192M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 203.07M 6.94M Sep/2025
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Sanofi EUR 397M 100M Dec/2025
Sarepta Therapeutics USD 395.74M 213.86M Sep/2025
United Therapeutics USD 297.7M 81.6M Sep/2025
Vertex Pharmaceuticals USD 1.95B 52.9M Sep/2025